Salvage therapy in refractory acute myeloid leukemia: prediction of outcome based on analysis of prognostic factors.

[1]  V. Heinemann,et al.  Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine , 1993, Annals of Hematology.

[2]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[3]  R. Willemze,et al.  A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). , 1997, Leukemia.

[4]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[5]  P. Sonneveld,et al.  Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia. , 1995, Leukemia.

[6]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[7]  X. Thomas,et al.  Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Territo,et al.  A randomized study of intermediate versus conventional‐dose cytarabine as intensive induction for acute myelogenous leukaemia , 1992, British journal of haematology.

[9]  F. Mitelman.  ISCN 1991 : guidelines for cancer cytogenetics : supplement to An international system for human cytogenetic nomenclature : recommendations of the Standing Committee on Human Cytogenetic Nomenclature, Subcommittee on Cancer Cytogenetics , 1992 .

[10]  T. Ahmed,et al.  Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia , 1991, Cancer.

[11]  M. Andreeff,et al.  Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. , 1989, Leukemia.

[12]  Edward J. Lee,et al.  Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. , 1989, Blood.

[13]  E. Gehan,et al.  Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. , 1988, Leukemia.

[14]  E. Estey,et al.  A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[16]  J. Kovach,et al.  Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia. , 1985, Medical and pediatric oncology.

[17]  J. Glick,et al.  High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Estey,et al.  Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Kahn,et al.  4'-(9‐acridinylamino)methane‐sulfon-m‐anisidide (m‐AMSA) and 5‐azacytidine (AZA) in the treatment of relapsed adult acute leukemia , 1983, American journal of clinical oncology.

[20]  R. Mertelsmann,et al.  Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine. , 1981, Cancer clinical trials.

[21]  B. Clarkson,et al.  Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia. , 1980, Cancer research.

[22]  A. Zander,et al.  4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia. , 1980, Annals of internal medicine.

[23]  Weiss Rb,et al.  m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program. , 1980 .

[24]  H. Preisler.  Failure of remission induction in acute myelocytic leukemia. , 1978, Medical and pediatric oncology.

[25]  G. Atwell,et al.  The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series. , 1974, European journal of cancer.

[26]  C. Spurr,et al.  Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. , 1968, Blood.